Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Safety Assessment Program has published peer-reviewed safety assessments covering over 2,000 fragrance materials in the peer-reviewed ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

ImmunoGen公司于2022年11月14日宣布美国食品药品监督管理局(FDA)已加速批准elahere(mirvetuximab soravtansine-gynx)用于治疗叶酸受体α(frα)阳性、铂耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌的成年患者，这些患者此前已接受了1至3次全身治疗方案。 适用症： 治疗叶酸 ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...